RESEARCH TRIANGLE PARK, N.C., March 26 /PRNewswire/ -- Quintiles Transnational Corp. today announced an agreement with Medca Japan to provide central laboratory services, further extending the Quintiles global network of laboratories certified by the College of American Pathologists (CAP).
Quintiles will have its own staff at the CAP-certified Medca Japan laboratory in Saitama, a city in the Greater Tokyo area. The lab will support clinical trials in Japan.
“Recent changes in legislation are allowing Japanese pharmaceutical companies to extend clinical trials normally conducted in Japan to other countries in Asia, but these companies have had difficulty finding central lab services that are harmonized throughout the region,” said Tom Wollman, Senior Vice President, Quintiles Global Central Laboratories. “With CAP-certified labs in Beijing, Singapore, Mumbai and now Japan, we can provide well- controlled processes and harmonized testing services throughout the Asia- Pacific region to customers in Japan as well as our multinational customers. This lab, along with all labs in our network, will follow the same standard operating procedures, and data will be available on our QNET database.”
“We have established excellent systems for providing high-quality central laboratory services based on Quintiles’ global standard,” said Yoh Narimatsu, President, Quintiles Transnational Japan K.K., a subsidiary of Quintiles Transnational. “We are determined to continue to increase clinical trials in Japan and provide superior services for our customers through this strategic business alliance.”
Yutaka Kannari, president of Medca Japan Laboratory Co., Ltd., said he was pleased that Medca has the capability and the high quality standards necessary to play an important role in the expansion of Quintiles’ business in Asia, and he also sees the alliance helping Medca.
“This collaboration with Quintiles will be very helpful for the future success of Medca Japan,” he said. “We receive more than 30,000 specimens for examination per day, and this relationship will allow us to strengthen out clinical trial services while supporting continued growth of our existing laboratory operations.”
Medca provides a broad range of laboratory services, including biochemical tests as well as endocrine testing, tumor marker testing, drug-level testing, immunology testing and microbiological testing. The laboratory has undertaken specimens for examination from about 4,000 medical institutions throughout Japan.
The relationship with Medca will be managed within Quintiles by Alan Ong, Vice President and General Manager, Quintiles Labs Asia, who will give technical guidance, and Narimatsu, who will provide his expertise on the Japan market.
CAP certification follows a site inspection. The accreditation is intended to improve patient safety by advancing the quality of pathology and laboratory services through education, setting standards and ensuring laboratories meet or exceed regulatory requirements.
About Quintiles Laboratories
Quintiles Laboratories owns a CAP-certified network of clinically harmonized facilities in the U.S., Europe, South Africa, India, China and Singapore, and has a tightly controlled network of sub-contractor laboratories in Argentina, Brazil and Japan managed by Quintiles employees located in each of the sub-contractor facilities.
About Quintiles Transnational Japan K.K.
Quintiles Transnational Japan K.K. is the Japanese subsidiary of Quintiles Transnational Corp. It is the largest contract pharmaceutical organization (CPO) in Japan to provide total solutions such as strategic marketing services and consultation. Quintiles Japan offers services from the Clinical Development Division, the commercialization division Innovex and NovaQuest, Quintiles’ strategic investment and partnering group. For further information, please visit the company’s website at http://www.quintiles.co.jp.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 19,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at www.quintiles.com.
CONTACT: Dick Jones, Media Relations, media.info@quintiles.com,
+1-919-998-2091, or Greg Connors, Investor Relations, invest@quintiles.com,
+1-919-998-2000
Web site: http://www.quintiles.com/
http://www.quintiles.co.jp/
